New Analysis Questions Affordability of GLP-1 Weight Loss Drugs at Scale
New analysis questions whether GLP-1 weight loss drugs can be affordably scaled to millions at current prices, as employers drop coverage and federal programs face trillion-dollar budget pressures.
Objective Facts
National GLP-1 spending rose by more than 500% between 2018 and 2023, from $13.7 billion to $71.7 billion, with the drugs estimated to account for 14% of all prescription drug spending in 2026, not counting direct-to-consumer sales. An estimated 34% of non-elderly people with employer-sponsored health insurance (36.2 million people) have a body mass index that would medically qualify them for a GLP-1 drug, and given the large number of potential beneficiaries, these medications could have a meaningful and long-term impact on healthcare costs. Several states have dropped Medicaid coverage due to costs, including California, New Hampshire, Pennsylvania, South Carolina, with Michigan restricting coverage to those classified as morbidly obese, and Rhode Island proposing to end coverage. A stark distinction exists between a treatment being "cost-effective" versus "affordable" — cost-effectiveness measures long-term benefits against cumulative costs, while affordability reflects a shorter-term view of whether payers have budgetary elasticity to absorb those new costs.
Left-Leaning Perspective
Ellen Kelsay, president and CEO of Business Group on Health, which represents the health policy interests of large employers, told reporters in May 2026 that companies cannot ignore that GLP-1s and overall prescription drug costs are fueling anticipated double-digit healthcare cost increases, leaving many to consider difficult coverage decisions. The survey of employer members found that while more than half of employers that cover GLP-1s for weight management expect significant clinical benefits, few have seen evidence of reduced obesity rates and fewer employees needing bariatric surgery within their aggregated claims. Dr. Matthew Klebanoff at a nonprofit health system described the challenge: patients should have access to these therapies, but it is very challenging for payers to afford covering them for everyone who could benefit, noting that one Pennsylvania hospital system's GLP-1 costs jumped to 40% of its insurance spending, leading to more than 600 employee layoffs, with the CEO stating the organization understands the value but cannot afford to pay for them right now. Progressive analysis frames the affordability crisis as a systemic market failure requiring structural reform. The Institute for Clinical and Economic Review emphasized that shorter-term budget impact and other considerations should always play a role in broader policy judgments, especially for products meant to serve such a large population of patients, and that given the immense scale of potential use of GLP-1s, lower prices might not solve affordability concerns for all payers. Research from the Health Management Academy found that even after recent price cuts, most states still face double-digit income burdens, with annual out-of-pocket costs often exceeding $3,000 per year, and in states with the highest income burdens and highest obesity rates like Mississippi, Louisiana, and West Virginia, the typical individual would need to spend roughly one-eighth of their annual income to maintain continuous GLP-1 treatment. Left-leaning coverage emphasizes equity concerns and market access disparities. The analysis omits discussion of supply-side constraints and competitive innovation as potential solutions, focusing instead on demand-side affordability barriers and payer burden as fundamental problems requiring direct government intervention to ensure equitable access.
Right-Leaning Perspective
The Trump administration framed GLP-1 price reductions as enabling fiscally sustainable Medicare expansion, arguing that the MFN drug pricing policy framework was carefully designed to work in tandem with U.S. trade policy efforts, such that while U.S. trade policy pushes foreign governments to pay their fair share, U.S. pricing commitments provide drug manufacturers with complimentary leverage in their negotiations with other wealthy nations. President Trump announced in November 2025 that average monthly costs of weight loss injections on TrumpRx would start around $350 and fall to about $250 within the next two years, with Dr. Susan Spratt of Duke noting the partnerships will improve access but questioning whether discounts will be enough to improve access to everyone who could benefit. CVS Caremark stated its formulary strategy uses competition to drive down costs while maintaining clinically appropriate coverage and enabling greater access, with spokesman Phillip Blando arguing that egregiously high list prices set by drug manufacturers are the single biggest barrier to patient access, and that through their expertise they are confident their formulary move means lower costs and better outcomes for consumers and customers. Conservative analysis frames affordability as a pricing problem, not a scale problem, solvable through market competition and direct-to-consumer channels rather than government coverage mandates. Both Novo Nordisk and Eli Lilly have launched direct-to-patient platforms offering GLP-1 medications at flat cash-pay rates significantly below the insurance list price, designed specifically for patients who either lost coverage or never had it, and President Trump's November 2025 pricing agreements set a new pricing precedent that may bring cash-pay costs down further. Access has also expanded through cash-pay programs, with Lilly starting LillyDirect in 2024 and Novo Nordisk following with NovoCare in March 2025, while Costco began selling Wegovy for $499 a month and Walmart rolled out a comparable arrangement with Lilly for Zepbound. Right-leaning coverage emphasizes price competition and manufacturer direct-to-consumer innovation as solutions, omitting discussion of coverage disparities for lower-income populations unable to access cash-pay options or requiring insurance intermediaries.
Deep Dive
The core affordability challenge is stark: GLP-1 spending rose over 500% between 2018-2023 (from $13.7B to $71.7B), and now accounts for an estimated 14% of all prescription drug spending in 2026, not counting direct-to-consumer sales. Crucially, ICER distinguished between "cost-effective" (long-term benefits exceed costs) and "affordable" (payers have budgetary elasticity to absorb costs in the short term), a distinction that frames the real policy dilemma: GLP-1s may eventually pay for themselves through prevented disease, but the upfront budget shock is unsustainable for many payers. With 36.2 million non-elderly people with employer-sponsored insurance meeting clinical criteria for GLP-1s, and with some projections suggesting the market could exceed $100 billion annually within five years, the scale problem is genuine regardless of unit price. Each side makes valid points. Progressive analysis correctly identifies that employer coverage is fragile, with two-thirds of employers currently covering GLP-1s for weight management but only 72% saying they will maintain coverage in 2027, and that research by GoodRx found 12 million people lost coverage for Zepbound and 12 million lost it for Wegovy from 2025 to 2026. Conservative analysis correctly notes that manufacturer direct-to-consumer programs now offer GLP-1 medications at flat cash-pay rates significantly below insurance list prices, with Trump's November 2025 pricing agreements setting a new precedent, suggesting market mechanisms can expand access without government expansion. What each side understates: Progressives tend to understate that real-world adherence and persistence are substantially lower than clinical trials, potentially limiting cost-effectiveness, meaning even subsidized access won't generate the long-term health ROI proponents project. Conservatives tend to understate that cash-pay programs only help the affluent and that in low-income states with the highest obesity rates, maintaining continuous GLP-1 treatment would require roughly one-eighth of annual income even at discounted rates, meaning market solutions alone will not achieve equitable access. The fact that CMS had to extend the Medicare GLP-1 Bridge from six months to 18 months because too few insurers signed on to the longer-term BALANCE Model by the April 2026 deadline suggests neither government nor market mechanisms have yet solved the affordability puzzle.